🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 22/02/2005 | 11,44 | 11,58 | 10,95 | 11,01 | -3,67% | 5,51% | 600.800 |
| 18/02/2005 | 11,70 | 11,70 | 11,11 | 11,43 | -0,61% | 5,04% | 773.100 |
| 17/02/2005 | 11,50 | 11,74 | 11,31 | 11,50 | +0,70% | 3,74% | 664.600 |
| 16/02/2005 | 11,43 | 11,51 | 11,19 | 11,42 | -0,09% | 2,80% | 565.800 |
| 15/02/2005 | 11,56 | 11,57 | 11,24 | 11,43 | +2,05% | 2,85% | 660.000 |
| 14/02/2005 | 11,60 | 11,80 | 11,10 | 11,20 | -3,03% | 6,03% | 558.900 |
| 11/02/2005 | 11,32 | 11,62 | 11,29 | 11,55 | +2,03% | 2,92% | 1.102.700 |
| 10/02/2005 | 10,55 | 11,47 | 10,55 | 11,32 | +7,30% | 8,72% | 901.100 |
| 09/02/2005 | 11,02 | 11,22 | 10,45 | 10,55 | -4,26% | 6,99% | 523.700 |
| 08/02/2005 | 11,20 | 11,50 | 10,82 | 11,02 | -0,90% | 6,07% | 551.200 |
| 07/02/2005 | 11,40 | 11,44 | 10,96 | 11,12 | -1,59% | 4,21% | 461.200 |
| 04/02/2005 | 10,50 | 11,42 | 10,50 | 11,30 | +6,91% | 8,76% | 804.500 |
| 03/02/2005 | 10,62 | 10,63 | 10,20 | 10,57 | +0,00% | 4,05% | 373.300 |
| 02/02/2005 | 10,75 | 10,75 | 10,39 | 10,57 | -1,31% | 3,35% | 453.200 |
| 01/02/2005 | 10,30 | 10,75 | 10,14 | 10,71 | +5,31% | 5,92% | 490.300 |
| 31/01/2005 | 10,24 | 10,35 | 10,04 | 10,17 | +1,19% | 3,03% | 392.500 |
| 28/01/2005 | 10,39 | 10,39 | 9,92 | 10,05 | -2,80% | 4,52% | 558.400 |
| 27/01/2005 | 10,54 | 10,57 | 10,21 | 10,34 | -2,08% | 3,42% | 369.300 |
| 26/01/2005 | 10,50 | 10,58 | 10,15 | 10,56 | +1,15% | 4,10% | 561.000 |
| 25/01/2005 | 10,30 | 10,66 | 10,20 | 10,44 | +2,35% | 4,47% | 591.000 |
| 24/01/2005 | 10,37 | 10,60 | 10,15 | 10,20 | +0,00% | 4,34% | 863.200 |
| 21/01/2005 | 10,62 | 10,65 | 10,13 | 10,20 | -3,13% | 4,90% | 576.200 |
| 20/01/2005 | 10,70 | 10,77 | 10,48 | 10,53 | +0,48% | 2,71% | 430.200 |
| 19/01/2005 | 10,95 | 11,28 | 10,40 | 10,48 | -3,05% | 8,04% | 485.000 |
| 18/01/2005 | 10,77 | 10,92 | 10,40 | 10,81 | +2,76% | 4,83% | 445.200 |
| 14/01/2005 | 10,40 | 10,73 | 10,39 | 10,52 | +1,25% | 3,27% | 550.500 |
| 13/01/2005 | 11,13 | 11,20 | 10,33 | 10,39 | -7,15% | 7,82% | 663.300 |
| 12/01/2005 | 11,02 | 11,19 | 10,52 | 11,19 | +2,47% | 6,08% | 683.200 |
| 11/01/2005 | 11,00 | 11,10 | 10,73 | 10,92 | +1,30% | 3,36% | 1.049.600 |
| 10/01/2005 | 10,95 | 11,19 | 10,71 | 10,78 | +2,76% | 4,38% | 871.900 |